background almost case human infect avian influenza ahn report since tandem prepared strategy include hn vaccine develop method value inactive observerblind studi health adult age year particle random receive asadjuv vaccine low medium dose hemagglutinin asa as one nonadjuv placebo coprimari immunogen object determine whether adj elicit immune response vaccinehomolog virus day second per unit state european license criterion perprotocol cohort n result met regulatory accept group receive formal seroconvers rate seroprotect geometry mean tier versus adj enhance antigenspar dose inject site pain occur frequent vaccine none serious adverse event relay vaccine concur two well tower induce robust antibody clinic trial register not 